Publications by authors named "Michael Mertzman"

Claim this Profile
I
Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage.
Amy C Hart, Lynn Abell, Junqing Guo, Michael E Mertzman, Ramesh Padmanabha

ACS Med Chem Lett· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of -Methyl Nicotinamide and -Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2).
Ryan Moslin, Yanlei Zhang, Stephen T Wrobleski, Shuqun Lin, Michael Mertzman

J Med Chem· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis.
Steven H Spergel, Michael E Mertzman, James Kempson, Junqing Guo, Sylwia Stachura

ACS Med Chem Lett· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Organic chemistry. Practical olefin hydroamination with nitroarenes.
Jinghan Gui, Chung-Mao Pan, Ying Jin, Tian Qin, Julian C Lo, Michael E Mertzman

Science· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of GS-9669, a thumb site II non-nucleoside inhibitor of NS5B for the treatment of genotype 1 chronic hepatitis C infection.
Scott E Lazerwith, Willard Lew, Jennifer Zhang, Philip Morganelli, Qi Liu, Michael Mertzman

J Med Chem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.
Martijn Fenaux, Stacey Eng, Stephanie A Leavitt, Yu-Jen Lee, Eric M Mabery, Michael Mertzman

Antimicrob Agents Chemother· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity.
X Christopher Sheng, Anthony Casarez, Ruby Cai, Michael O Clarke, Xiaowu Chen, Michael Mertzman

Bioorg Med Chem Lett· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV Inhibitors.
Scott E Lazerwith, Gina Bahador, Eda Canales, Guofeng Cheng, Lee Chong, Michael Mertzman

ACS Med Chem Lett· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel, potent, and orally bioavailable phosphinic acid inhibitors of the hepatitis C virus NS3 protease.
Michael O Clarke, Xiaowu Chen, Aesop Cho, William E Delaney, Edward Doerffler, Michael Mertzman

Bioorg Med Chem Lett· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of benzofuran for concomitant protection of aldehyde and phenol groups in the preparation of mycophenolic acid analogues.
Maria Fardis, Michael Mertzman, William Thomas, Thorsten Kirschberg, Nicole Collins

J Org Chem· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis